Recently, the Class 1 innovative drug Senaparib Capsules (trade name: 派舒宁/Paishuning) of Shanghai Inpai Pharmaceutical Co., Ltd. is approved for marketing by China NMPA. This product is indicated for the maintenance treatment of adult patients with advanced epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, who have achieved complete or partial response following first-line platinum-based chemotherapy. The approval of this drug provides a new treatment option for relevant patients.